

In the claims:

Please amend claims as follows (for the convenience of the Examiner, all claims, whether or not amended, are presented below):

8. (Amended) - An(active) immunoglobulin fusion protein (Ig-fusion protein) obtained by culturing a mammalian host cell transformed with DNA encoding the fusion in a culture system having a low temperature of about 27° C to about 35 ° C.

A3 9. (Amended) The Ig-fusion protein of claim 8 comprising a member of the TNF family. ✓

10. (Amended) The Ig-fusion protein of claim 9 comprising LT-B receptor. ✓

11. (Amended) The Ig-fusion protein of claim 9 comprising herpes virus entry mediator (HVEM).

16. (Amended) A pharmaceutical preparation obtained by

- A4
- (a) culturing a host transformed with DNA encoding an Ig-fusion protein in a culture system having a low temperature of about 27° C to about 32 ° C, thereby expressing active Ig-fusion proteins;
 - (b) recovering active Ig-fusion proteins from said culture system; and
 - (c) combining the active Ig-fusion proteins of step (b) with a pharmaceutically acceptable carrier.

17. (Amended) The pharmaceutical preparation of claim 16 wherein the Ig- fusion protein comprises a member of the TNF family.

18. (Amended) The pharmaceutical preparation of claim 17 wherein the Ig- fusion protein comprises a lymphotoxin-B receptor.

A4 19. (Amended) The pharmaceutical preparation of claim 17 wherein the Ig-fusion protein comprises HVEM.

26. (Amended) An active Ig-fusion protein obtained by culturing yeast transformed with DNA encoding the fusion in a culture system having a low temperature of about 10° C to about 25 ° C.

A5 27. (Amended) The Ig-fusion protein of claim 26 comprising a member of the TNF family.

28. (Amended) The Ig-fusion protein of claim 27 comprising LT-B receptor, or a fragment thereof.

29. (Amended) The Ig-fusion protein of claim 26 comprising HVEM, or a fragment thereof.
